Pharm
Carboplatin
search
Carboplatin
, Paraplatin
See Also
Alkylating Agent
Cisplatin
Indications (Part of combination protocols)
FDA approved
Ovarian Cancer
Off-Label Use
Adenocarcinoma (unknown primary)
Bladder Cancer
Breast Cancer
Cervical Cancer
Endometrial Cancer
(advanced)
Head and neck squamous cell cancer
Leukemia
(Acute)
Lung Cancer
(squamous cell, non-small cell and small cell)
Lymphoma
(Hodgkin or Non-Hodgkin)
Melanoma
Mesothelioma
Neuroendocrine Tumors
Prostate Cancer
Sarcoma
Testicular Cancer
(Germ Cell)
Mechanism
Second-generation platinum based
Antineoplastic Agent
More stable and less toxic than its parent drug
Cisplatin
Components
Platinum atom
Ammonia groups (2)
Cyclobutane-dicarboxyl residue
Activated intracellularly as reactive platinum complexes
Binds DNA (e.g. GC rich regions)
Results in DNA cross-links
Results in cell growth inhibition, apoptosis and cell death
Medications
Carboplatin IV Solution (10 mg/ml) in 5 ml, 15 ml, 45 ml and 60 ml vials
Dosing
See other references for disease specific dosing protocols
Adverse Effects
Alopecia
Bone Marror Suppression (esp. with comorbid
Renal Insufficiency
)
Hepatotoxicity with increased
Liver Function Test
s
Nephrotoxicity
Peripheral Neuropathy
Secondary Malignancy
Vomiting
Safety
Avoid in
Lactation
Pregnancy Category D
Avoid in Pregnancy (all trimesters)
Use reliable
Contraception
Monitoring
Complete Blood Count
Renal Function
tests
Liver Function Test
s
Drug Interactions
Decreases
Phenytoin
levels
Efficacy
Similar efficacy as
Cisplatin
for
Lung Cancer
and
Ovarian Cancer
Decreased efficacy compared with
Cisplatin
for germ cell tumors,
Bladder Cancer
, head and neck cancer
Resources
Carboplatin (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3ae9880-44bb-4f4e-93d8-8a5e21708a30
Type your search phrase here